Selection of contrast media

Kidney International

Volumn 69, Issue SUPPL. 100, 2006, Pages

  Solomon, R ^a   Biguori, C ^b   Bettmann, M ^c  

^a UNIVERSITY OF VERMONT   (United States)

^b Clinica Mediterranea   (Italy)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Contrast media; Contrast media osmolality; Contrast induced nephropathy

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; CREATININE; DOPAMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; IOBITRIDOL; IODINATED CONTRAST MEDIUM; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPENTOL; IOVERSOL; IOXAGLIC ACID; IOXILAN; THEOPHYLLINE; IODINE; RADIOPHARMACEUTICAL AGENT;

ACUTE KIDNEY FAILURE; ANGIOGRAPHY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DETERIORATION; DIALYSIS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY DYSFUNCTION; NEPHROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; X RAY; CHEMICAL STRUCTURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CLASSIFICATION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; OSMOLARITY; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

CONTRAST MEDIA; GADOLINIUM; HUMANS; IODINE; KIDNEY DISEASES; MOLECULAR STRUCTURE; OSMOLAR CONCENTRATION; RADIOPHARMACEUTICALS; RANDOMIZED CONTROLLED TRIALS; X-RAYS;

EID: 33746879223     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000373     Document Type: Article

References (66)

1. Campbell D, Flemming BK, Mason WF et al. A comparative study of the nephrotoxicity of iohexol, iopamidol, and ioxaglate in peripheral angiography. J Can Assoc Radiol 1990; 41: 133-137.
2. Tepel M, Van Der Giet M, Schwarzfeld C et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-184.
3. Becker C, Reiser MF. Use of iso-osmolar nonionic dimeric contrast media in multidetector row computed tomography angiography for patients with renal impairment. Invest Radiol 2005; 40: 672-675.
4. Carraro M, Malalan F, Antonione R et al. Effects of a dimeric vs a monomeric nonionic contrafast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Eur Radiol 1998; 8: 144-147.
5. Kohemainen H, Soiva M. Comparison of Xenetrix 300 and Visipaque 320 in patients with renal failure. Eur Radiol 2003; 13: B32 (abstract P 27).
6. Lufft V, Hoogestrast-Lufft L, Fels LM et al. Contrast media nephrotoxicity: intravenous CT angiography versus intraarterial digital subtraction angiography in renal artery stenosis: a prospective randomized trial. Am J Kidney Dis 2002; 40: 236-242.
7. Vliestre R, Nunn CM, Naverte J, Browne KF. Contrast nephropathy after coronary angioplasty in chronic renal insufficiency. Am Heart J 1996; 32: 1049-1050.
8. Mason R, Arbeit LA, Giron R. Renal dysfunction after angiography. JAMA 1985; 253: 1001-1004.
9. Freeman R, O'Donnell M, Share D et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002; 90: 1068-1073.
10. Cigarroa R, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86: 649-652.
11. Manske C, Sprafka JM, Strong JH, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89: 615-620.
12. McCullough P, Wolyn R, Rocher LL et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-375.
13. Briguori C, Manganelli F, Scarpato P et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002; 40: 298-303.
14. Noto T, Johnson LE, Krone R et al. Cardiac catheterization 1990: a report of the registry of the Society for Cardiac Angiography and Interventions. Cathet Cardiovasc Diagn 1991; 24: 75-83.
15. Rieger J, Sitter T, Toepfer M et al. Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant 2002; 17: 824-828.
16. Hatrick A, Jarosz JM, Irvine AT. Gadopentate dimeglumine as an alternative contrast agent for use in interventional procedures. Clin Radiol 1997; 12: 948-952.
17. Hammer F, Goffette PP, Malaise J, Mathurin P. Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography. Eur Radiol 1999; 9: 128-136.
18. Townsend R, Cohen DL, Katholi R et al. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. Am J Kidney Dis 2000; 36: 1207-1212.
19. Tombach B, Bremer C, Reimer P et al. Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology 2001; 218: 651-657.
20. Sam A, Morasch MD, Collins J et al. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 2003; 38: 313-318.
21. Kim M, Kim H. Gadolinium dimeglumine as a contrast agent for digital subtraction angiography: in vitro Hounsfield unit measurement and clinical efficacy. Yonsei Med J 2003; 44: 138-142.
22. Kaufman J, Geller SC, Bazari H, Waltman AC. Gadolinium-based contrast agents as an alternative at vena cavography in patients with renal insufficiency: early experience. Radiology 1999; 212: 280-284.
23. Hoffmann U, Fischereder M, Reil A et al. Renal effects of gadopentetate dimeglumine in patients with normal and impaired renal function. Eur J Med Res 2005; 10: 149-154.
24. Prince M, Arnoldus C, Frisoli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging 1996; 1: 162-166.
25. Ailawadi G, Stanley JC, Williams DM et al. Gadolinium as a non nephrotoxic contrast agent for catheter-based arteriographic evaluation of renal arteries in patients with azotemia. J Vasc Surg 2003; 37: 346-352.
26. Bokhari S, Wen YHJ, Winters R. Gadolinium-based percutaneous coronary intervention in a patient with renal insufficiency. Catheter Cardiovasc Interv 2003; 58: 358-361.
27. Sarkis A, Badaoui G, Slaba S et al. Gadolinium-based coronarography in a patient with renal failure: first clinical report. Catheter Cardiovasc Interv 2001; 54: 68-69.
28. Gemery J, Idelson B, Reid S et al. Acute renal failure after arteriography with a gadolinium-based contrast agent. Am J Roentgenol 1998; 171: 1277-1278.
29. Gemmete J, Forauer AR, Kazanjian S et al. Safety of large volume gadolinium angiography (abst). J Vasc Interv Radiol 2001; 12: S28.
30. Erley C, Bader BD, Berger ED et al. Gadolinium-based contrast media compared with iodinated media for digital-substraction angiography in azotemic patients. Nephrol Dial Transplant 2004; 19: 2526-2531.
31. Nyman U, Elmstahl B, Leander P et al. Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia? Radiology 2002; 223: 311-318.
32. Brillet B, Dubois M, Beaufils H et al. Renal tolerance of gadolinium-DOTA and gadolinium-DTPA in rats. Invest Radiol 1994; 29: 352-354.
33. Thomsen H, Almen T, Morcos SK, members of the Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR). Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 2002; 12: 2600-2605.
34. Barrett B, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1998; 188: 171-178.
35. Jakobsen J, Berg KJ, Brodahl U et al. Renal effects of nonionic contrast media after cardioangiography. Acad Radiol 1994; 35: 191-196.
36. Davidson C, Hlatky M, Morris KG et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization: a prospective trial. Ann Intern Med 1989; 110: 119-124.
37. Rudnick M, Goldfarb S, Wexler L et al. Nephropathy of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int 1995; 47: 254-261.
38. Solomon R. The role of osmolality in the incidence of contrast induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 2005; 68: 2256-2263.
39. Newhouse J, Landman J, Lang E et al. Efficacy and safety of iopromide for excretory urography. Invest Radiol 1994; 29(Suppl 1): S68-S73.
40. Garcia-Ruiz C, Martinez-Vea A, Sempere T et al. Low risk of contrast nephropathy in high-risk patients undergoing spiral computed tomography angiography with the contrast medium iopromide and prophylactic oral hydration. Clin Nephrol 2004; 61: 170-176.
41. Lundqvist S, Holmberg G, Jakobsson G et al. Assessment of possible nephrotoxicity from iohexol in patients with normal and impaired renal function. Acta Radiol 1998; 39: 362-367.
42. Fischbach R, Landwehr P, Lackner K et al. Iodixanol vs iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase-III trial. Eur Radiol 1996; 6: 9-13.
43. Klow N, Levorstad K, Berg KJ et al. Iodixanol in cardioangiography in patients with coronary artery disease: tolerability, cardiac and renal effects. Acta Radiol 1993; 34: 72-77.
44. Pugh N, Sissons GRJ, Ruttley MST. Iodixanol in femoral arteriography (phase III): a comparative double-blind parallel trial between iodixanol and iopromide. Clin Radiol 1993; 47: 96-99.
45. Singh K, Sundgren R, Bolstad B et al. Iodixanol in abdominal digital subtraction angiography: a randomized double-blind parallel trial with iodixanol and iohexol. Acta Radiol 1993; 34: 242-245.
46. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999; 72: 701-703.
47. Tadros G, Malik JA, Manske CL et al. Iso-osmolar radiocontrast iodixanol in patients with chronic kidney disease. J Invasive Cardiol 2005; 17: 211-215.
48. Aspelin P, Aubry P, Fransson S et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348: 491-499.
49. Briguori C, Colombo A, Airoldi F et al. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int 2005; 68: 2250-2255.
50. Hans S, Hans BA, Dhillon R et al. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am Surgeon 1998; 64: 432-436.
51. Durham J, Caputo C, Dokko J et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002; 62: 2202-2207.
52. Miner S, Szavik V, Nguyen-Ho P et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J 2004; 148: 690-695.
53. Rashid S, Salman M, Myint F et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg 2004; 40: 1136-1141.
54. Taliercio C, Vlietstra RE, Ilstrup DM et al. A randomized comparison of nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. J Am Coll Cardiol 1991; 17: 384-390.
55. Shyu K, Cheng JJ, Kuan P. Acetylcysteine protects against renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2004; 40: 1383-1388.
56. Kay J, Chow WH, Chan TM et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention. JAMA 2003; 289: 553-558.
57. Oldemeyer J, Biddle WP, Wurdeman RL et al. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 2003; 146(6): E23.
58. Goldenberg I, Shechter M, Matetsky S et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: a randomized controlled trial and review of the current literature. Eur Heart J 2004; 25: 212-218.
59. Webb J, Pate GE, Humphries KH et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 2004; 148: 422-429.
60. Abizaid A, Clark CE, Mintz GS et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999; 83: 260-263.
61. Fung J, Szeta CC, Chan WWM et al. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis 2004; 43: 801-808.
62. Diaz-Sandoval L, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002; 89: 356-358.
63. Huber W, Schipek C, Ilgmann K et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003; 91: 1157-1162.
64. Marenzi G, Marana I, Lauri G et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349: 1333-1340.
65. Baker C, Wragg A, Kumar S et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003; 41: 2114-2118.
66. Boccalandro F, Amhad M, Smalling RW et al. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003; 58: 336-341.